Novanta Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Novanta heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 4.6%, terwijl de Electronic-industrie de winst zag groeien met 4.2% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 9.3%. Het rendement op eigen vermogen van Novanta is 4.1%, en het heeft een nettomarge van 5.5%.
Belangrijke informatie
4.57%
Groei van de winst
4.06%
Groei van de winst per aandeel
| Electronic Groei van de industrie | 15.34% |
| Inkomstengroei | 9.31% |
| Rendement op eigen vermogen | 4.10% |
| Nettomarge | 5.49% |
| Volgende winstupdate | 11 May 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Analyse-update • Apr 19
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.Analyse-update • Apr 05
NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.Analyse-update • Mar 22
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.Analyse-update • Mar 06
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.Analyse-update • Feb 20
NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.Analyse-update • Feb 06
NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).Analyse-update • Jan 22
NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.Analyse-update • Jan 08
NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.Analyse-update • Dec 24
NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.Analyse-update • Dec 10
NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).Analyse-update • Nov 26
NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.Analyse-update • Nov 10
NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.Analyse-artikel • Oct 28
Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...Analyse-artikel • Oct 07
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...Seeking Alpha • Sep 29
Novanta: The Solution To Elevated Expectations Is Lower Prices
Summary Novanta Inc. remains a trusted technology partner for OEMs, but recent growth has been modest and organic performance underwhelming. Despite a strong track record and niche positioning, Novanta trades at a demanding 30x earnings multiple, currently posting quite flattish growth. Recent results show minimal sales and earnings growth, while NOVT leverage is set to rise due to a $200 million buyback program. I remain on the sidelines, seeking a lower entry point and a higher earnings yield to justify NOVT stock's premium and ensure a margin of safety. Read the full article on Seeking AlphaAnalyse-artikel • Sep 13
Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Analyse-update • Sep 05
Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.Analyse-artikel • Aug 29
Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 69.2x Novanta Inc. ( NASDAQ:NOVT ) may be sending very bearish signals at...Analyse-artikel • Jun 16
Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for Novanta is US$95.22 based on 2 Stage Free Cash Flow to Equity Novanta is...Analyse-artikel • May 20
Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Apr 06
Novanta: A Trusted Yet Premium Technology Partner
Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 01
Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
Nieuwe analyse • Aug 28
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Opbrengsten en kosten
Opbrengsten en kosten
Hoe Novanta geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 25 | 981 | 54 | 196 | 95 |
| 26 Sep 25 | 960 | 53 | 188 | 98 |
| 27 Jun 25 | 957 | 61 | 181 | 97 |
| 28 Mar 25 | 952 | 71 | 179 | 96 |
| 31 Dec 24 | 949 | 64 | 177 | 96 |
| 27 Sep 24 | 923 | 60 | 175 | 94 |
| 28 Jun 24 | 900 | 62 | 170 | 92 |
| 29 Mar 24 | 893 | 69 | 168 | 92 |
| 31 Dec 23 | 882 | 73 | 165 | 92 |
| 29 Sep 23 | 888 | 76 | 161 | 90 |
| 30 Jun 23 | 890 | 77 | 162 | 89 |
| 31 Mar 23 | 876 | 73 | 160 | 88 |
| 31 Dec 22 | 861 | 74 | 159 | 86 |
| 30 Sep 22 | 841 | 73 | 156 | 83 |
| 01 Jul 22 | 796 | 64 | 147 | 79 |
| 01 Apr 22 | 748 | 58 | 137 | 75 |
| 31 Dec 21 | 707 | 50 | 130 | 73 |
| 01 Oct 21 | 655 | 49 | 122 | 69 |
| 02 Jul 21 | 621 | 44 | 117 | 67 |
| 02 Apr 21 | 598 | 44 | 111 | 64 |
| 31 Dec 20 | 591 | 45 | 110 | 61 |
| 02 Oct 20 | 603 | 41 | 112 | 60 |
| 03 Jul 20 | 614 | 42 | 113 | 58 |
| 03 Apr 20 | 624 | 40 | 118 | 57 |
| 31 Dec 19 | 626 | 41 | 119 | 56 |
| 27 Sep 19 | 623 | 43 | 117 | 54 |
| 28 Jun 19 | 629 | 56 | 119 | 54 |
| 29 Mar 19 | 625 | 57 | 119 | 53 |
| 31 Dec 18 | 614 | 51 | 116 | 51 |
| 28 Sep 18 | 605 | 39 | 115 | 50 |
| 29 Jun 18 | 591 | 18 | 113 | 48 |
| 30 Mar 18 | 559 | 12 | 108 | 44 |
| 31 Dec 17 | 521 | 40 | 102 | 42 |
| 29 Sep 17 | 473 | 48 | 94 | 38 |
| 30 Jun 17 | 425 | 55 | 86 | 34 |
| 31 Mar 17 | 403 | 54 | 82 | 33 |
| 31 Dec 16 | 385 | 22 | 81 | 32 |
| 30 Sep 16 | 376 | 20 | 80 | 31 |
| 01 Jul 16 | 371 | 19 | 80 | 31 |
| 01 Apr 16 | 369 | 34 | 81 | 31 |
| 31 Dec 15 | 374 | 36 | 82 | 31 |
| 02 Oct 15 | 377 | 1 | 85 | 32 |
| 03 Jul 15 | 380 | 0 | 86 | 32 |
Kwaliteitswinsten: NOVT heeft een grote eenmalige verlies van $22.7M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 31st December, 2025.
Groeiende winstmarge: De huidige netto winstmarges (5.5%) NOVT } zijn lager dan vorig jaar (6.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van NOVT is de afgelopen 5 jaar met 4.6% per jaar gegroeid.
Versnelling van de groei: De winstgroei NOVT is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: NOVT had het afgelopen jaar een negatieve winstgroei ( -16% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Electronic ( 12.5% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 4.1% ) van NOVT wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/07 05:00 |
| Aandelenkoers aan het einde van de dag | 2026/05/07 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Novanta Inc. wordt gevolgd door 8 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |